We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers (INFLUX-IT-VS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01082484
First Posted: March 8, 2010
Last Update Posted: October 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Grenoble
  Purpose
The purpose of this study is to test whether prostacyclin analogues' cathodal iontophoresis induce a cutaneous vasodilation in healthy volunteers's forearm, without local side effects.

Condition Intervention Phase
Healthy Drug: treprostinil Drug: iloprost Drug: NaCl 0.9% Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by University Hospital, Grenoble:

Primary Outcome Measures:
  • Amplitude of forearm cutaneous vasodilatation assessed using laser Doppler imaging [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Local tolerance assessed clinically [ Time Frame: Day 0 and after 7 days ]

Estimated Enrollment: 20
Study Start Date: January 2010
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treprostinil
Treprostinil iontophoresis (250, 25 and 2.5 microM)
Drug: treprostinil
Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Experimental: Iloprost
Iloprost iontophoresis (200, 20 and 2 microM)
Drug: iloprost
Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Placebo Comparator: NaCl 0.9% Drug: NaCl 0.9%
Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy volunteers
  • age above 18

Exclusion Criteria:

  • any chronic disease
  • any drug intake
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01082484


Locations
France
Unité de Pharmacologie Clinique, Inserm CIC3, CHU Grenoble
Grenoble, France, 38043
Sponsors and Collaborators
University Hospital, Grenoble
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Grenoble
ClinicalTrials.gov Identifier: NCT01082484     History of Changes
Other Study ID Numbers: 2009-016301-42
First Submitted: February 9, 2010
First Posted: March 8, 2010
Last Update Posted: October 6, 2011
Last Verified: October 2011

Keywords provided by University Hospital, Grenoble:
Healthy volunteers
iontophoresis

Additional relevant MeSH terms:
Treprostinil
Iloprost
Antihypertensive Agents
Platelet Aggregation Inhibitors
Vasodilator Agents